Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...